Global Gene Therapy Market Size, Share, Trends & Growth Analysis Report 2026-2034

Description

The Gene Therapy Market size is expected to reach USD 42.11 Billion in 2034 from USD 8.50 Billion (2025) growing at a CAGR of 19.45% during 2026-2034.

The global gene therapy market is witnessing significant growth due to advancements in biotechnology and increasing focus on treating genetic disorders. Gene therapy involves modifying or replacing defective genes to treat or prevent diseases, offering potential cures for conditions that were previously considered untreatable. Rising investments in research and development are significantly driving market expansion.

Key drivers include increasing prevalence of genetic disorders, growing demand for personalized medicine, and advancements in gene editing technologies such as CRISPR. Pharmaceutical and biotechnology companies are actively developing innovative therapies, supported by favorable regulatory frameworks. Additionally, collaborations and funding initiatives are accelerating clinical trials and product development.

Looking ahead, the market is expected to expand with the introduction of new therapies and improved delivery systems. Advances in viral vectors and non-viral methods will enhance safety and effectiveness. As scientific research continues to progress, the gene therapy market is poised for transformative growth and significant impact on global healthcare.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Indication

Large B-Cell Lymphoma
Multiple Myeloma
Spinal Muscular Atrophy (SMA)
Acute Lymphoblastic Leukemia (ALL)
Melanoma (lesions)
Inherited Retinal Disease
Beta-Thalassemia Major/SCD
Others

By Vector Type

Lentivirus
RetroVirus & gamma RetroVirus
AAV
Modified Herpes Simplex Virus
Adenovirus
Others

By Route of Administration

Intravenous
Others

COMPANIES PROFILED

Amgen Inc, Novartis AG, F HoffmannLa Roche, Gilead Sciences Inc, bluebird bio Inc, BristolMyers Squibb Company, Legend Biotech, BioMarin, uniQure NV, Merck Co, Sarepta Therapeutics Inc
We can customise the report as per your requirements.

Product Code: VMR11218241

Chapter 1. PREFACE

1.1. Market Segmentation & Scope
1.2. Market Definition
1.3. Information Procurement
- 1.3.1 Information Analysis
- 1.3.2 Market Formulation & Data Visualization
- 1.3.3 Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

2.1. Market Snapshot
2.2. Segmental Outlook
2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

3.1. Market Lineage Outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Value Chain Analysis
3.4. Regulatory Framework
- 3.4.1 Standards & Compliance
- 3.4.2 Regulatory Impact Analysis
3.5. Market Dynamics
- 3.5.1 Market Drivers
- 3.5.2 Market Restraints
- 3.5.3 Market Opportunities
- 3.5.4 Market Challenges
3.6. Porter's Five Forces Analysis
3.7. PESTLE Analysis

Chapter 4. GLOBAL GENE THERAPY MARKET: BY INDICATION 2022-2034 (USD MN)

4.1. Market Analysis, Insights and Forecast Indication
4.2. Large B-Cell Lymphoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.3. Multiple Myeloma Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.4. Spinal Muscular Atrophy (SMA) Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.5. Acute Lymphoblastic Leukemia (ALL) Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.6. Melanoma (lesions) Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.7. Inherited Retinal Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.8. Beta-Thalassemia Major/SCD Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.9. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL GENE THERAPY MARKET: BY VECTOR TYPE 2022-2034 (USD MN)

5.1. Market Analysis, Insights and Forecast Vector Type
5.2. Lentivirus Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.3. RetroVirus & gamma RetroVirus Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.4. AAV Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.5. Modified Herpes Simplex Virus Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.6. Adenovirus Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL GENE THERAPY MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

6.1. Market Analysis, Insights and Forecast Route Of Administration
6.2. Intravenous Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.3. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL GENE THERAPY MARKET: BY REGION 2022-2034 (USD MN)

7.1. Regional Outlook
7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.2.1 By Indication
- 7.2.2 By Vector Type
- 7.2.3 By Route Of Administration
- 7.2.4 United States
- 7.2.5 Canada
- 7.2.6 Mexico
7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.3.1 By Indication
- 7.3.2 By Vector Type
- 7.3.3 By Route Of Administration
- 7.3.4 United Kingdom
- 7.3.5 France
- 7.3.6 Germany
- 7.3.7 Italy
- 7.3.8 Russia
- 7.3.9 Rest Of Europe
7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.4.1 By Indication
- 7.4.2 By Vector Type
- 7.4.3 By Route Of Administration
- 7.4.4 India
- 7.4.5 Japan
- 7.4.6 South Korea
- 7.4.7 Australia
- 7.4.8 South East Asia
- 7.4.9 Rest Of Asia Pacific
7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.5.1 By Indication
- 7.5.2 By Vector Type
- 7.5.3 By Route Of Administration
- 7.5.4 Brazil
- 7.5.5 Argentina
- 7.5.6 Peru
- 7.5.7 Chile
- 7.5.8 Rest of Latin America
7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.6.1 By Indication
- 7.6.2 By Vector Type
- 7.6.3 By Route Of Administration
- 7.6.4 Saudi Arabia
- 7.6.5 UAE
- 7.6.6 Israel
- 7.6.7 South Africa
- 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

8.1. Recent Developments
8.2. Company Categorization
8.3. Supply Chain & Channel Partners (based on availability)
8.4. Market Share & Positioning Analysis (based on availability)
8.5. Vendor Landscape (based on availability)
8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL GENE THERAPY INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Company Profiles
- 9.2.1 Amgen Inc
- 9.2.2 Novartis AG
- 9.2.3 F. Hoffmann-La Roche
- 9.2.4 Gilead Sciences Inc
- 9.2.5 Bluebird Bio Inc
- 9.2.6 Bristol-Myers Squibb Company
- 9.2.7 Legend Biotech
- 9.2.8 BioMarin
- 9.2.9 UniQure N.V
- 9.2.10 Merck & Co
- 9.2.11 Sarepta Therapeutics Inc